Alliancebernstein L.P. Has $504,000 Stake in Omeros Co. (NASDAQ:OMER)

Alliancebernstein L.P. grew its stake in shares of Omeros Co. (NASDAQ:OMER) by 153.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 50,990 shares of the biopharmaceutical company’s stock after acquiring an additional 30,870 shares during the quarter. Alliancebernstein L.P.’s holdings in Omeros were worth $504,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its position in Omeros by 31.3% in the 4th quarter. JPMorgan Chase & Co. now owns 32,134 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 7,667 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Omeros in the 4th quarter valued at about $46,000. Mindset Wealth Management LLC lifted its holdings in shares of Omeros by 4.8% in the fourth quarter. Mindset Wealth Management LLC now owns 63,000 shares of the biopharmaceutical company’s stock valued at $622,000 after purchasing an additional 2,875 shares in the last quarter. Picton Mahoney Asset Management boosted its position in shares of Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 4,404 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Omeros during the fourth quarter worth about $1,120,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Price Performance

Omeros stock opened at $6.78 on Monday. The business has a 50 day moving average of $8.01 and a 200-day moving average of $7.88. The company has a market capitalization of $393.67 million, a P/E ratio of -2.94 and a beta of 2.35. Omeros Co. has a 1 year low of $2.97 and a 1 year high of $13.60.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.08. During the same quarter last year, the business posted ($0.15) EPS. Equities analysts anticipate that Omeros Co. will post -3.09 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Tuesday, April 1st. StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, April 9th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Friday, April 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.